张亚伟,康晓迪,郝文静,邢 宇,刘丽恒,刘麒薇.地屈孕酮联合口服黄体酮胶丸对黄体功能不全先兆流产患者血清抑制素A、性激素的影响[J].现代生物医学进展英文版,2022,(4):669-673. |
地屈孕酮联合口服黄体酮胶丸对黄体功能不全先兆流产患者血清抑制素A、性激素的影响 |
Effect of Dydrogesterone Combined with Oral Progesterone Capsule on Serum Statin A and Sex Hormones in Patients with Threatened Abortion with Luteal Insufficiency |
Received:May 31, 2021 Revised:June 27, 2021 |
DOI:10.13241/j.cnki.pmb.2022.04.015 |
中文关键词: 地屈孕酮 黄体酮胶丸 黄体功能不全 先兆流产 抑制素A 性激素 |
英文关键词: Dydrogesterone Progesterone capsule Luteal insufficiency Threatened abortion Statin A Sex hormones |
基金项目:北京市自然科学基金项目(7214228);首都医科大学附属北京妇产医院中青年学科骨干培养专项(FCYY201914) |
|
Hits: 846 |
Download times: 373 |
中文摘要: |
摘要 目的:探讨地屈孕酮联合口服黄体酮胶丸对黄体功能不全先兆流产患者血清抑制素A、性激素的影响。方法:选择2018年9月到2020年9月在我院接受治疗的125例黄体功能不全先兆流产患者,采用随机数表法分为试验组(n=63)和对照组(n=62)。对照组给予黄体酮胶丸治疗,试验组在对照组的基础上给予地屈孕酮治疗。比较两组临床疗效、抑制素A、雌二醇(E2)、孕酮(P)、人绒毛膜促性腺激素(HCG)、临床症状改善情况、妊娠结局及不良反应发生情况。结果:治疗后,两组总有效率比较差异显著(P<0.05);治疗前,试验组和对照组血清抑制素A、E2、P、HCG比较无显著差异;治疗后试验组和对照组血清抑制素A、E2、P、HCG随着时间的推移而升高,且试验组均高于对照组,差异显著(P<0.05);试验组止血时间、腹痛改善时间及腰痛改善时间均显著低于对照组,差异显著(P<0.05);试验组保胎成功率、新生儿体质量及新生儿Apgar评分均显著高于对照组,差异显著(P<0.05);两组不良反应总发生率分别为7.94%、9.68%(P>0.05)。结论:在黄体功能不全先兆流产患者中应用地屈孕酮联合口服黄体酮胶丸效果显著,可能与其可有效改善血清抑制素A、性激素水平有关,且不增加不良反应。 |
英文摘要: |
ABSTRACT Objective: To study Effect of dydrogesterone combined with oral progesterone capsule on serum statin A and sex hormones in patients with threatened abortion with luteal insufficiency. Methods: 125 patients with threatened abortion with luteal insufficiency treated in our hospital from September 2018 to September 2020 were divided into experimental group (n=63) and control group (n=62) by random number table method. The control group was treated with progesterone capsule, and the experimental group was treated with dydrogesterone on the basis of the control group. Clinical efficacy, statin A, estradiol (E2), progesterone (P), human chorionic gonadotropin (HCG), improvement of clinical symptoms, pregnancy outcome and the incidence of adverse reactions were compared between the two groups. Results: After treatment, the total effective rate between the two groups was significantly different (P<0.05). Before treatment, there were no significant differences in serum statin A, E2, P and HCG between the experimental group and the control group. After treatment, the serum levels of statin A, E2, P and HCG in experimental group and control group were increased with the passage of time, and the difference was significant(P<0.05). The hemostasis time, improvement time of abdominal pain and improvement time of low back pain in experimental group were significantly lower than those in control group, the differences were significant (P<0.05); The success rate of fetal preservation, neonatal body weight and Apgar score of neonates in experimental group were significantly higher than those in control group (P<0.05). The total incidence of ADR in the two groups was 7.94% and 9.68% (P>0.05). Conclusion: In patients with threatened abortion with luteal insufficiency, the application of dydrogesterone combined with oral progesterone capsule has significant effect, which may be related to the effective improvement of serum statin A and sex hormone levels without increasing adverse reactions. |
View Full Text
View/Add Comment Download reader |
Close |
|
|
|